Valuation: Gain Therapeutics, Inc.

Market Cap 5.22Cr 4.68Cr 4.33Cr 3.92Cr 7.32Cr 496.72Cr 7.41Cr 52Cr 21Cr 259.92Cr 20Cr 19Cr 825.16Cr P/E 2026 *
-2.41x
P/E 2027 * -1.83x
Enterprise Value 5.22Cr 4.68Cr 4.33Cr 3.92Cr 7.32Cr 496.72Cr 7.41Cr 52Cr 21Cr 259.92Cr 20Cr 19Cr 825.16Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.77%
Yield 2026 *
-
Yield 2027 * -
1 day+1.26%
1 week-6.59%
Current month-30.35%
1 month-28.27%
3 months-28.70%
6 months-31.53%
Current year-62.58%
1 week 1.14
Extreme 1.14
1.34
1 month 1.14
Extreme 1.14
1.84
Current year 1.14
Extreme 1.14
3.29
1 year 1.14
Extreme 1.14
4.34
3 years 0.89
Extreme 0.89
5.33
5 years 0.89
Extreme 0.89
9.7
10 years 0.89
Extreme 0.89
17.93
Manager TitleAgeSince
Chief Executive Officer 52 25/06/2024
Chief Tech/Sci/R&D Officer - 25/03/2024
Chief Tech/Sci/R&D Officer - 01/09/2020
Director TitleAgeSince
Chairman 69 01/01/2017
Director/Board Member 63 01/05/2019
Director/Board Member 58 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

Director

25,000 0.0586%
15/07/26 Free

Founder

25,000 0.0586%
15/07/26 Free

Director

25,000 0.0586%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%-6.59%-33.79%-58.73% 5.22Cr
+0.34%-3.03%+37.45%+61.06% 6.41TCr
+1.03%+2.73%+12.31%+84.00% 5.55TCr
+1.48%+1.69%+12.94%+105.07% 5.3TCr
-0.63%-0.31%+27.37%+56.61% 4.6TCr
-0.31%-2.76%+18.06%+99.20% 4.25TCr
+0.79%+1.09%+227.03%+934.03% 4.04TCr
-0.26%-4.20%+10.86%+45.18% 3.23TCr
-2.07%+42.73%+103.77%+90.26% 3.45TCr
-2.72%-8.79%+22.58%-5.63% 2.42TCr
Average -0.11%+3.48%+43.86%+141.10% 3.93TCr
Weighted average by Cap. +0.00%+3.13%+49.55%+160.92%

Financials

2026 *2027 *
Net sales - -
Net income -2.18Cr -1.96Cr -1.81Cr -1.64Cr -3.06Cr -207.82Cr -3.1Cr -22Cr -8.62Cr -108.75Cr -8.19Cr -8.02Cr -345.23Cr -3.32Cr -2.98Cr -2.75Cr -2.49Cr -4.66Cr -316.23Cr -4.72Cr -33Cr -13Cr -165.48Cr -12Cr -12Cr -525.32Cr
Net Debt - -
Projected Income Statement - Annual - Gain Therapeutics, Inc.
Logo Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Employees
-
Date Price Change Volume
29/26/29 $1.205 +0.84% 81,768
28/26/28 $1.195 +2.14% 4,00,425
27/26/27 $1.170 +1.74% 5,08,340
26/26/26 $1.150 -8.73% 8,11,024
23/26/23 $1.260 -2.33% 6,45,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Gain Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.195USD
Average target price
7.200USD
Spread / Average Target
+502.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gain Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GANX Stock